Dr. Reddy’s Bachupally Facility Receives USFDA Observations Amid Global Expansion Moves

has received a Form 483 with five observations from the USFDA following a pre-approval inspection at its Bachupally biologics facility between September 4–12, 2025, and the company has confirmed it will respond within the stipulated timeline. This development comes soon after Dr. Reddy’s announced a $50.5 million acquisition of Janssen’s Stugeron portfolio, covering 18 markets across Asia-Pacific and EMEA, with India and Vietnam as key growth drivers. On the financial side, Q1FY26 revenue stood at ₹8,542 crore (vs. ₹7,672.7 crore YoY), net profit was ₹1,417.8 crore (vs. ₹1,392 crore YoY), and EBITDA came in at ₹2,287 crore, broadly in line with estimates. The company continues to guide for double-digit topline growth with stable margins, underscoring both regulatory challenges and expansion-driven opportunities. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.